Celecoxib Has Potent Antitumour Effects As A Single Agent And In Combination With BCG Immunotherapy In A Model Of Urothelial Cell Carcinoma

Main Category: Urology / Nephrology
Also Included In: Cancer / Oncology
Article Date: 02 Mar 2008 - 0:00 PDT

email to a friend   printer friendly   opinions  

The authors evaluated the role of Celecoxib, an inhibitor of Prostaglandin E(2) (PGE(2)), which is a potent immune modulator in the treatment of urothelial cancer. PGE(2) is known to suppress both tumour antigen-specific helper T (T(H)1) cells and the generation of cytotoxic T lymphocytes (CTLs). The authors hypothesized that a combination of the cyclooxygenase 2 (COX-2) selective inhibitor celecoxib and intravesical bacillus Calmette-Guérin (BCG), an effective tumor immunoprophylaxis and ablative therapy for non-muscle-invasive bladder cancer, would be more effective than BCG alone.

To test their hypothesis the authors assessed urinary levels of PGE(2) in humans receiving BCG and in a murine model of urothelial cell carcinoma (UCC). The cytokine response to BCG plus celecoxib was assessed in murine dendritic cells (DCs) in vitro and tumor ablation was assessed in an orthotopic MBT2 murine bladder cancer model. Administration of intravesical BCG resulted in elevated urinary PGE(2) levels in patients with high-grade superficial UCC and in a mouse model of UCC. Activation of DCs with BCG stimulated COX-2 up-regulation and release of PGE(2) and interleukin 10. In a superficial mouse model of UCC, combination of celecoxib and intravesical BCG therapy resulted in increased tumor infiltration of CD4(+) T cells and improved efficacy when compared to BCG alone.

The authors concluded that a combination strategy involving BCG immunotherapy and celecoxib may be more therapeutically beneficial than stand-alone intravesical therapy. There were several clinical trials evaluating celecoxib in the prevention of bladder cancer. These trials were discontinued due to the cardiac risk profile associated with celecoxib.

Dovedi SJ, Kirby JA, Davies BR, Leung H, Kelly JD

Eur Urol. 2008 Jan 15
10.1016/j.eururo.2008.01.013

Reported by UroToday.com Contributing Editor David P. Wood, MD Professor and Chief of Urological Oncology Department of Urology University of Michigan Medical School Ann Arbor, MI

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

----------------------------
Copyright © 2007 - UroToday
Reproduced for Medical News Today with permission of UroToday.
----------------------------

• Additional
• References
• Citations